【复星医药(02196.HK)：复星医药产业就FXS7553用于治疗慢性阻塞性肺疾病于中国境内启动Ⅱ期临床试验】智通财经APP讯，复星医药(02196.HK)发布公告，近日，上海复星医药(集团)股份有限公司(以下简称“本公司”)控股子公司上海复星医药产业发展有限公司(以下简称“复星医药产业”)就FXS7553(原项目代号：XH-S004)用于治疗慢性阻塞性肺疾病于中国境内启动Ⅱ期临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.